Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMGECIJ)

• Drug Name: Blinatumomab Drug Info
• Synonyms: AMG 103; Blincyto

Indication

Disease Entry	ICD 11	Status	REF
Acute lymphoblastic leukaemia	2A85	Approved	[1]
B-cell acute lymphoblastic leukaemia	2B33.3	Approved	[2]
Diffuse large B-cell lymphoma	2A81	Phase 2/3	[3]

• Cross-matching ID: TTD Drug ID: DMGECIJ

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
B-lymphocyte surface antigen B4 (CD19)	TTW640A	CD19_HUMAN	Modulator	[4]
T-cell surface glycoprotein CD3 (CD3)	TTUN7MC	NOUNIPROTAC	Modulator	[4]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
B-lymphocyte surface antigen B4 (CD19)	DTT	CD19	5.758	6.211	6.083	5.396

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

• The Studied Disease: Acute lymphoblastic leukaemia
• ICD Disease Classification: 2A85

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
B-lymphocyte surface antigen B4 (CD19)	DTT	CD19	2.33E-24	-1.06	-1.33

References

• [1] ClinicalTrials.gov (NCT02013167) Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
• [2] Blinatumomab, a bispecific B-cell and T-cell engaging antibody, in the treatment of B-cell malignancies. Hum Vaccin Immunother. 2019;15(3):594-602.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.